Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2016, Article ID 1368481, 5 pages
Research Article

Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection

1Retina Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
3School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Received 21 March 2016; Revised 31 July 2016; Accepted 18 September 2016

Academic Editor: Roberta Cavalli

Copyright © 2016 Mojtaba Abrishami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (). Diclofenac was quantified in samples up to 48 hours after intraocular injection. Four hours after intravitreal injection, the concentration of diclofenac in vitreous and aqueous humor of eyes receiving SLNs was, respectively, 2.5 and 6.5 times higher than eyes injected with commercial form of drug. Conclusions. Here, we demonstrate the potential of SLNs as a carrier of diclofenac for intraocular injection in order to prevent the systemic effects of the drug, increase the injection intervals, and improve the patient compliance.